Gilead Sciences

Open: 76.12 Close: 77.89 Change: 1.77

Our AI found unexpected things about Gilead Sciences Company Inc.

The game is changing. There is a new strategy to evaluate Gilead Sciences fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, share, stock, Inc, Q1, earnings, …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Zacks Research decreased their Q1 2024 earnings per share estimates for shares of Gilead Sciences in a note issued to investors on Wednesday, May 31st. Remdesivir has a low risk of serious side effects and is a valuable addition to the fight against Ebola.

Today's News

Gilead Sciences, Inc. (Gild) statistics & valuation metrics - stock analysis. gilead sciences, inc. (gild) Statistics & Valuation Metrics - Stock Analysis. Zacks Research decreased their Q1 2024 earnings per share estimates for shares of Gilead Sciences in a note issued to investors on Wednesday, May 31st. The consensus estimate is $6.74 per share and Q1 2025 earnings at $1.60 per share. Remdesivir was originally developed by Gilead Sciences to treat Ebola virus infections but has gained worldwide attention due to its potential to treat COVID-19. Remdesevir has a low risk of serious side effects and is a valuable addition to the fight against the virus. Shares of Gilead Sciences Inc. close GILD +2.20% SPX +1.45% DJIA +2.12% JNJ +1.57% PFE +0.89% ABT +1%. GILD is listed as a manufacturer of drugs and pharmaceuticals. Gilead Sciences is an attractive income stock. Overall, we think this could be an attractive yield-yielding income stock, and it is only getting better by paying a higher dividend this year. Taking a bit further, weve identified 3 warning signs that investors need to be conscious.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

How much time have you spent trying to decide whether investing in Gilead Sciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, share, stock, Inc, Q1, earnings, and the most common words in the summary are: gilead, science, inc, subscribe, stock, see, new, . One of the sentences in the summary was: Zacks Research decreased their Q1 2024 earnings per share estimates for shares of Gilead Sciences in a note issued to investors on Wednesday, May 31st. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #inc #subscribe #stock #see #new.